KS-KCAS
KCAS Bioanalytical and Biomarker Services (KCAS), a leading bioanalytical contract research organization (CRO), backed by Vitruvian Partners, closed the purchase of Active Biomarkers, located in Lyon, France. Active Biomarkers is a renowned assay development and specialty bioanalytical laboratory with expertise in oncology, infectious disease, inflammation and neurodegenerative disorders. Financial terms were not disclosed. Formerly owned by its management team and Turenne Santé fund, Active Biomarkers operates in a new, state-of-the-art facility in Lyon, France with significant expansion opportunities. This transaction adds valuable bioassay and cellular analysis expertise as well as European capacity to support customers globally as KCAS continues to advance its mission of providing high quality bioassay services to the biotech and pharmaceutical industries. The acquisition of Active Biomarkers is the second in 2022 by KCAS. FlowMetric, a leading flow cytometry and cellular analysis CRO, joined KCAS in early 2022. The Lyon site adds to KCAS and FlowMetric’s existing facilities in Kansas, Philadelphia and Milan, Italy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220912005063/en/
Active Biomarkers building in Lyon, France (Photo: Business Wire)
John Bucksath, CEO of KCAS, stated “We are delighted to partner with the Active Biomarkers team, accelerating our combined offering to support the customers we serve globally. The combined expertise and capacity of KCAS, FlowMetric, and Active Biomarkers is unique. The high-quality, science-first and client-centric culture we all share is key to our commitment to become the CRO partner of choice for the global pharma and biopharma industries. KCAS has embarked on significant investments, including a purpose-built 70,000 sq. ft. facility in Kansas City and a 26,000 sq. ft. facility in Pennsylvania, and accelerating our international footprint through acquisitions. We continue to attract the industry’s top scientific talent and focus on outstanding science and customer service. With our investors, Vitruvian Partners, we are optimally positioned to invest in our people and deliver world-class services for our growing client base. The acquisition of Active Biomarkers gives our combined clients access to further scientific expertise and support in both markets regionally and internationally.”
Marc Essodaigui, CEO of Active Biomarkers, comments, “Our entire team is thrilled about the new partnership with KCAS and the combined organizations’ outlook. This combination will allow us to provide even more comprehensive, best-in-class services for the biopharma and life sciences sector. The KCAS’ alliance, backed by a leading world-class growth investor, will provide us with the support and growth to expand our technological expertise, capacity, and geographical footprint.”
Sophie Bower-Straziota, Partner at Vitruvian Partners, comments, “Active Biomarkers has built a strong reputation in Europe founded in scientific excellence. The company fits with our investment strategy of backing best-in-class operations offering services to a market with strong tailwinds and internationalization opportunities. The acquisition of Active Biomarkers by KCAS builds on the excellent foundation KCAS has built in the US and supports the increasingly international needs of the company’s growing pharmaceutical and biotech clients. As the drug development market continues to evolve, we will continue to support investment in scientific capabilities, broadening geographical reach, providing the resources to scale the business, and making strategic acquisitions.”
About KCAS - KCAS is a rapidly growing company that provides comprehensive GLP compliant development services from early discovery support through product registration and beyond. One of only a select few CROs offering both large and small molecule development with extensive capabilities and expertise, KCAS provides a truly differentiated approach to its clients who are looking for both scientific expertise and excellent customer service. KCAS is headquartered in Olathe, Kansas – the Kansas City metro area and employs more than 300 employees. Website: KCASBio.com.
About Active Biomarkers – Founded in 2011, Active Biomarkers is an integrated bioanalytical laboratory offering a wide range of services, including PK, immunogenicity, soluble and cellular biomarker analyses for clinical studies. Operating in state-of-the-art BSL2 facilities, GCLP accredited and ISO 9001:2015 certified, the company has a unique track-record in the development, validation, and implementation of analytical methods. Its expert team has supported hundreds of studies in multiple therapeutic areas: oncology, infectious diseases, inflammatory pathologies, and neurodegenerative diseases. Beyond its state-of the-art flow cytometry and ELISpot capabilities, Active Biomarkers offers the broadest panel of immunoassay technologies in Europe, ranging from standard ELISA to multiplexed methods such as Luminex, SP-X or ELLA systems, or ultra-sensitive technologies such as MSD, Gyrolab or Simoa HD-X platforms. Website: active-biomarkers.com
About Vitruvian - Vitruvian is a leading international growth investor headquartered in London with additional offices in Stockholm, Madrid, Munich, Luxembourg, San Francisco, Singapore and Shanghai. Vitruvian focuses on dynamic situations characterized by rapid growth and change across industries. Vitruvian has backed over 90 companies and has assets under management of approximately €10 billion. Website: vitruvianpartners.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005063/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Legora Raises $150 Million Series C to Accelerate Global Rollout of Its AI Platform for Legal Professionals30.10.2025 11:00:00 CET | Press release
Legora, the collaborative AI platform for lawyers, today announced the completion of a Series C round of $150 million at a $1.8 billion valuation, led by Bessemer Venture Partners, with significant investment from existing investors ICONIQ, General Catalyst, Redpoint Ventures, Benchmark, and Y Combinator, to accelerate its global expansion and growing product roadmap. The funding round takes place against a backdrop of rapidly increasing demand for Legora’s AI-powered platform for legal professionals over the past six months. Since May 2025, Legora’s customer base has grown from 250 to over 400, while the number of markets served has doubled from 20 to more than 40. Legora now partners with many of the world’s most prestigious enterprises and law firms – including Linklaters, Cleary Gottlieb, Goodwin, and MinterEllison – not just as customers, but as strategic collaborators. Tens of thousands of legal professionals use Legora every day to review and research with precision, draft smart
IFF Honors Distinguished Academics Shaping the Future of Nutrition, Health and Biosciences30.10.2025 11:00:00 CET | Press release
IFF Science Awards honor Dr. Carles Lerín and Prof. Jan Maarten van Dijl for contributions to nutrition, microbiome science and antimicrobial research IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences — announced the recipients of its IFF Science Awards, recognizing Dr. Carles Lerín of Institut de Recerca Sant Joan de Déu in Barcelona, Spain, and Prof. Jan Maarten van Dijl of the University Medical Center Groningen in Groningen, Netherlands, for their outstanding contributions to the fields of human health, nutrition and antimicrobial research. The IFF Science Awards honor individuals for their remarkable achievements in science, specifically within food, the microbiome, nutrition, health, biocatalysis and sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030622387/en/ Photo credit: Dr. Carles Lerín “Breakthrough innovation thrives on collaboration. By partneri
Codethink Achieves Positive Functional Safety Assessment to IEC 61508 and ISO 26262 Standards for the Eclipse Trustable Software Framework30.10.2025 10:04:00 CET | Press release
Codethink announced that it has successfully achieved a positive and complete Functional Safety Assessment for the Eclipse Trustable Software Framework (TSF). Performed by exida, a globally recognised authority in functional safety, the assessment was conducted in accordance with IEC 61508 requirements, with domain experts ensuring full alignment and compatibility with ISO 26262, the automotive industry’s functional safety standard. The evaluation represents a major milestone in Codethink’s mission to transform how the world engineers, verifies, and trusts software. According to the assessment, “considering the process objectives of both IEC 61508 and ISO 26262, the specification of Trustable [Trustable Software Framework] and the reference implementation that maps Trustable tenets and assertions to the objectives in IEC 61508, it is determined that Trustable sets out an approach to software development which meets and in many cases exceeds the rigor and expectations established for so
GHK Capital-Backed Horizon Group Welcomes Kasper Diaz Sommer as Senior Vice President of Global Cruise Logistics30.10.2025 10:00:00 CET | Press release
Horizon Group, along with its subsidiaries Swift Marine and Delver Agents, proudly announces the appointment of Kasper Diaz Sommer as Senior Vice President (SVP) of Global Cruise Logistics, effective November 3, 2025. Based in Denmark, Kasper will lead the group’s global Cruise Logistics strategy, driving growth across Europe, Asia, and the Americas and strengthening Horizon’s role as the trusted logistics partner to the world’s leading marine and cruise operators. With over two decades of international leadership experience in freight forwarding, logistics, and maritime supply chains, Kasper is known for his hands-on leadership, customer-first mindset, and proven success in building high-performing global teams. “Kasper’s leadership will accelerate our strategy to deliver seamless, end-to-end logistics solutions for the world’s marine and cruise operators,” said Jeff McCorstin, CEO of Horizon. “His industry insight, strategic mindset, and passion for innovation align perfectly with ou
Ares Management to Acquire BlueCove30.10.2025 09:18:00 CET | Press release
Integrated Business to Form Newly Created Ares Systematic Credit Strategy Ares Management Corporation (NYSE: ARES) (“Ares”) announced today that one of its affiliates has entered into a definitive agreement to acquire the entire outstanding share capital of BlueCove Limited (“BlueCove”), a London-based systematic fixed income manager. Financial terms were not disclosed. The transaction is expected to close in the first quarter of 2026, subject to customary closing conditions, including regulatory approvals. Founded in 2018 by Alex Khein and Hugh Willis – who have respectively served as CEO and Executive Chairman – BlueCove has grown to become a leader in systematic credit investing. The firm is comprised of a highly experienced, long-tenured team of fixed income investment, engineering, and business infrastructure professionals specializing in systematic portfolio management. Through its proprietary technology and varied product offering, BlueCove invests in high-yield, corporate inves
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom